Other

Johnson and Johnson Vision Care, Inc.

Eth Zurich

Sumitomo Chemical Company, Limited

Lonza Inc.

Lipideon Biotechnology Ag

Johnson Matthey Inc.

Stemergie Biotechnology Sa

Swiss Cannapharmaceutical Sa

Bristol-myers Squibb Compnay

Essilor International

Carreira, Erick M.

Erick Moran Carreira

Weili Zhao

Aleksander Warm

Nicka Chinkov

Bernd Wollscheid

Hiroshi Kadono

Kazuo Murakami

Meinrad Brenner

Nadine Sobotzki

Lothar Zimmermann

Miriam Lorenzi

Damien Barbaras

Thomas Fessard

Michael Andreas Schafroth

Brian Adger

Helmut Hauser

Dong-Bo Li

Roman Sarott

Patrick Pfaff

Konrad Hurni

Jürg Stäubli

Remo Roth

Sarah Eichenberger

Bettina Meissburger

Andreas Frei

Moritz Werder

Tobias Ritter

Lisbet Kvaerno

Ock-Youm Jeon

Virginie Clement-Schatlo

Joana Matos

Susanne Wolfrum

Jeon Ockyoum

Shoji Fukuyo

The present invention relates to tri-functional crosslinking reagents carrying (i) a ligand-reactive group for conjugation to a ligand of interest having at least one binding site on a target glycoprotein receptor, (ii) a hydrazone group for the capturing of oxidized receptor-glycoproteins and (iii) an affinity group selected from azides and aklynes for the detection, isolation and purification of captured glycoproteins; as well as their manufacturing. The invention further provides for improved methods of detecting, identifying and characterizing interactions between ligands and their corresponding target glycoproteins on living cells and in biological fluids. The invention further provides for new uses of catalysts in such methods.

Tri-functional crosslinking reagents

In a method for aromatizing an alicyclic region of a cannabinoid, especially in enantiopure, scalemic and/or racemic form, in particular for aromatizing the cyclohexene group in Δ-THC-C, Δ-THCA-CA, Δ-THCV-C, Δ-THCVA-CA, and/or scalemic or racemic mixtures of these substances, wherein an oxidizing agent is added to the cannabinoid, sulfur is used as the oxidizing agent.

Conversion of THC, CBD and their derivatives to Cannabinol

The present invention relates to tri-functional crosslinking reagents carrying (i) a ligand-reactive group for conjugation to a ligand of interest having at least one binding site on a target glycoprotein receptor, (ii) a hydrazone group for the capturing of oxidized receptor-glycoproteins and (iii) an affinity group selected from azides and alkynes for the detection, isolation and purification of captured glycoproteins; as well as their manufacturing. The invention further provides for improved methods of detecting, identifying and characterizing interactions between ligands and their corresponding target glycoproteins on living cells and in biological fluids. The invention further provides for new uses of catalysts in such methods.

The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention, suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, as well as methods of treatment or prevention of such diseases.

ROR gamma modulators

The present invention relates to trifunctional crosslinking reagents carrying (i) a ligand-reactive group for conjugation to a ligand of interest having at least one binding site on a target glycoprotein receptor, (ii) an optionally protected aromatic hydrazine group for the capturing of oxidized receptor-glycopeptides and (iii) an affinity group for the detection, isolation and purification of captured glycopeptides, their methods of production, as well as their use in methods for detecting, identifying and characterizing interactions between ligands and their corresponding glycoprotein target receptors on living cells and in biological fluids.

Trifunctional crosslinking reagents

The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumor-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit.

Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof

The present invention relates to novel azetidinone-containing compounds having a novel side-chain which is attached to the aryl ring at C4 via a C&#x2014;C bond and comprises a 3,3-disubstituted oxetane ring and a polar group A, and which are useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels.

Pharmaceutical hypocholesterolemic compositions

The invention is directed to a process for the preparation of a cyclic carbamate starting with o-aminobenzyl alcohol and/or a suitable salt thereof, which is reacted with a cyclization agent selected from phosgene, diphosgene, triphosgene and mixtures thereof, and in that the reaction carried out in the presence of an aqueous base, and a water-immiscible organic solvent, said organic solvent mainly comprising at least one compound selected from C-alkyl C-carboxylates and mixtures of at least one C-alkyl C-carboxylate with at least one C-alkane.

Process for the synthesis of cyclic carbamates

The invention is directed to a process for the preparation of a cyclic carbamate starting with a chiral propargylic alcohol and/or a suitable salt thereof, which is reacted with a cyclization agent selected from phosgene, diphosgene, triphosgene and mixtures thereof, and in that the reaction is carried out in the presence of an aqueous base, and a water-immiscible organic solvent, said organic solvent mainly comprising at least one compound selected from C-alkyl C-carboxylates and mixtures of at least one C-alkyl C-carboxylate with at least one C-alkane. Another aspect of the invention is directed to a process for the synthesis of said cyclic carbamate starting described above, wherein also a process for the preparation of the chiral propargylic alcohol is provided.

An autocatalytic process for the synthesis of chiral propargylic alcohols.

Autocatalytic process for the synthesis of chiral propargylic alcohols

A process for the preparation of the compound of formula 

Process for the synthesis of a propargylic alcohol

The invention relates to a chiral iridium aqua complex of formula (1): wherein Rand Rare the same or different and each is an aryl group optionally having at least one substituent selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a haloalkoxy group having 1 to 6 carbon atoms, a nitro group, a carboxyl group and a cyano group, or the like; and wherein Rand Rare the same or different and each is an alkyl group or the like, as well as the use of such a chiral iridium aqua complex for asymmetric transfer hydrogenation.

Chiral iridium aqua complex and method for producing optically active hydroxy compound by using the same

The present invention provides a production method of an allylic amine represented by the formula (III): wherein Ris as defined in the specification,which comprises reacting by an allylic alcohol represented by the formula (II): wherein Ris as defined in the specification,with sulfamic acid, in the presence of a phosphoramidite ligand represented by the formula (I): wherein each symbol is as defined in the specification, and an iridium complex. According to the present invention, a primary allylic amine can be produced directly from an allylic alcohol, without use of an activator for an allylic alcohol and conversion of an allylic alcohol into an activated compound thereof.

Phosphoramidite ligand and production method of allylic amine using the same

An optically active nitro compound having two hydrogen atoms on its &#x3b1;-carbon atom and having &#x3b2;-asymmetric carbon atom can be produced by making &#x3b1;,&#x3b2;-unsaturated nitroolefin having a hydrogen atom on its &#x3b1;-carbon atom react with at least two organosilicon compounds having at least one silicon-hydrogen bond in the molecule in the presence of an asymmetric copper complex, or react with an organosilicon compound having at least one silicon-hydrogen bond in the molecule in the presence of an asymmetric copper complex and water.

Method for producing an optically active nitro compound

The present invention provides a compound represented by the formula (I): wherein ring A is void or a benzene ring optionally having substituent(s), Rand Rare each independently a phenyl group optionally having substituent(s), a cyclohexyl group and the like, Rand Rare each independently a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group and the like, and X is a residue represented by &#x2014;ORor &#x2014;NHRwherein Rand Rare a lower alkyl group optionally having substituent(s), an aralkyl group optionally having substituent(s) and the like, a asymmetric transition metal complex containing the compound as a ligand and a production method of optically active compound using the complex as an asymmetric catalyst.

Growing community of inventors

Zumikon, Switzerland

Erick Moran Carreira